<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138589</url>
  </required_header>
  <id_info>
    <org_study_id>201900032</org_study_id>
    <nct_id>NCT04138589</nct_id>
  </id_info>
  <brief_title>Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function</brief_title>
  <acronym>ROOTS</acronym>
  <official_title>Real World Data of the Effect of Lumacaftor/Ivacaftor Therapy in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marien Hospital Wesel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain prospective real world data of the effect of lumacaftor/ivacaftor or tezacaftor/&#xD;
      ivacaftor on small airway disease in children aged 6-18 years with cystic fibrosis (CF)&#xD;
      homozygous for F508del. The effect of the medication on small airway disease is evaluated by&#xD;
      measurement of multiple breath washout (MBW) with its outcome parameter lung clearance index&#xD;
      (LCI) and the Perth-Rotterdam Annotated Grid Morphometric Analysis for CF (PRAGMA-CF)&#xD;
      cpmputed tomography (CT) score. In addition the relation between changes in LCI and PRAGMA-CF&#xD;
      score is evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center observational study. Duration 12 months after the start of lumacaftor/ ivacaftor&#xD;
      or tezacaftor/ ivacaftor .&#xD;
&#xD;
      To collect these data and to assist in clinical decisions regarding initiation and&#xD;
      continuation of lumacaftor/ivacaftor or tezacaftor/ ivacaftor, the investigators of the CF&#xD;
      center (Beatrix Children's Hospital, University Medical Center Groningen (UMCG), the&#xD;
      Netherlands) developed an extensive protocol of testing before children aged 6-18 years start&#xD;
      therapy and during the first year after start.&#xD;
&#xD;
      The protocol includes the following tests: growth parameters, sweat test, lung function&#xD;
      testing (spirometry, MBW, body plethysmography), blood test panel (AST, ALT, alkalic&#xD;
      phosphatase (AF), total and direct bilirubin, LDH), fecal elastase, high resolution (HR)CT&#xD;
      and CF quality of life questionnaires. These tests are repeated at regular intervals.&#xD;
&#xD;
      Multi-center observational study. Duration 12 months after the start of lumacaftor/ ivacaftor&#xD;
      or tezacaftor/ ivacaftor .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lung clearance index</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PRAGMA-CF score</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </secondary_outcome>
  <other_outcome>
    <measure>percent predicted forced expiratory volume in 1 second</measure>
    <time_frame>12 months</time_frame>
    <description>t= 0 and t-=12</description>
  </other_outcome>
  <other_outcome>
    <measure>percent predicted forced vital capacity measured by spirometry</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Residual volume measured by blodypethysmography</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Residual volume/ total lung capacity measured by blodypethysmography</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Mid upper arm circumference in SDS</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight SDS</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Sweat chloride level</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>CF questionnaire revised respiratory domain</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12, scale 0-100</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis in Children</condition>
  <arm_group>
    <arm_group_label>CF patients aged 6-18 years homozygeous for delta F508</arm_group_label>
    <description>CF patients aged 6-18 years homozygeous for delta F508 starting with lumacaftor/ ivacaftor or tezacaftor/ ivacaftor</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are included from the Beatrix Children's Hospital, UMCG, the Netherlands and the&#xD;
        Marien Hospital Wesel, Germany&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children aged 6-18 years&#xD;
&#xD;
          -  CF, Homozygote F508del confirmed by DNA analysis&#xD;
&#xD;
          -  Considered for start of lumacaftor/ ivacaftor or tezacaftor/ivacaftor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Unable to perform acceptable, repeatable lung function tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Annelies M Zwitserloot, MD</last_name>
    <phone>+31625649950</phone>
    <email>a.m.zwitserloot@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brigitte WM Willemse, MD, phd</last_name>
    <phone>+31503616161</phone>
    <email>b.w.m.willemse@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Marien Hospital Wesel</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Gappa, MD, Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatrix Children's Hospital, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies M Zwitserloot, MD</last_name>
      <phone>+31625649950</phone>
      <email>a.m.zwitserloot@umcg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.M. Zwitserloot</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>lumacaftor/ ivacaftor</keyword>
  <keyword>tezacaftor/ ivacaftor</keyword>
  <keyword>Multiple breath washout</keyword>
  <keyword>Lung clearance index</keyword>
  <keyword>PRAGMA CF score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

